What is Applied Biosciences Corp?
focuses on the development and commercialization of synthetic cannabinoid therapeutics/biopharmaceuticals that target the endocannabinoid system to treat a range of diseases across various therapeutic areas.
APPB · Verdict
Moderate reward · high risk
APPB's standout is valuation; volatility and profitability weigh on the picture.
Based on 88% data coverage
APPB · Verdict
Above average
Weak vs peers
-372% net margin · -222% ROE
-128% free-cash-flow margin
Earnings +199.3% CAGR
Current ratio 0.95
Model-based scoring. For information only — not financial advice.
focuses on the development and commercialization of synthetic cannabinoid therapeutics/biopharmaceuticals that target the endocannabinoid system to treat a range of diseases across various therapeutic areas. It delivers consumer and OTC THC-free CBD products that promote overall health and wellbeing, as well as testing and analytics capabilities to its customers. The company is listed on the OTCCE in USA, operating in the Healthcare sector, with a market capitalisation of 2.20K.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.